New drug could shield preemie lungs from chronic disease
NCT ID NCT05898633
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new drug called rfhSP-D in 18 premature babies born before 30 weeks. The goal was to find the safest dose that might prevent chronic lung disease, a common complication in preemies. The drug was given along with standard care to babies on breathing machines.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
recombinant surfactant protein D (rfhSP-D)
What this could lead to
If successful, this could lead to a new treatment to prevent chronic lung disease in premature infants, reducing lifelong breathing problems.
What could go wrong
This is a very early Phase 1 trial with only 18 babies, focused on safety. The drug may not work or could have side effects. Much more research is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHOPULMONARY DYSPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University College London Hospitals
London, United Kingdom